ImmunoPrecise and Biotheus partner on bispecific antibodies to treat cancer [Yahoo! Finance]
ImmunoPrecise Antibodies Ltd. (IPA)
Company Research
Source: Yahoo! Finance
material transfer and evaluation agreement (MTEA) with Biotheus on bispecific antibodies to treat cancer. The agreement focuses on the development of a new bispecific antibody therapy targeting hypoxic solid tumours using Talem Therapeutics' TATX-20 lead candidate. Under the MTEA, Biotheus will receive the specialised antibody asset from Talem Therapeutics, a subsidiary of ImmunoPrecise Antibodies and plans to utilise it alongside its proprietary technology to create new drugs for cancer. These therapeutics aim to simultaneously target two different tumour markers, offering a potential breakthrough in cancer treatment, especially for tumours in oxygen-deprived environments. Biotheus co-founder, chair, and CEO Xiaolin Liu said: “We are happy to enter into a collaboration with ImmunoPrecise Antibodies, a leading AI-driven biotech with powerful multi-omics modelling expertise. “Biotheus' broad expertise in antibody discovery and development is powered by our fully integrated ca
Show less
Read more
Impact Snapshot
Event Time:
IPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPA alerts
High impacting ImmunoPrecise Antibodies Ltd. news events
Weekly update
A roundup of the hottest topics
IPA
News
- $20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer TherapiesBusiness Wire
- ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation [Yahoo! Finance]Yahoo! Finance
- ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics InnovationBusiness Wire
- ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI TechnologyBusiness Wire
- ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024Business Wire
IPA
Earnings
- 9/16/24 - Miss
IPA
Analyst Actions
- 9/17/24 - HC Wainwright
IPA
Sec Filings
- 11/18/24 - Form 6-K
- 11/13/24 - Form 6-K
- 11/4/24 - Form 6-K
- IPA's page on the SEC website